BioInvent International AB (BOVNF)
4.70
0.00 (0.00%)
USD |
OTCM |
Jun 14, 16:00
BioInvent International Revenue (TTM): 5.746M for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 5.746M |
| December 31, 2023 | 6.732M |
| September 30, 2023 | 7.222M |
| June 30, 2023 | 6.447M |
| March 31, 2023 | 32.89M |
| December 31, 2022 | 33.12M |
| September 30, 2022 | 31.74M |
| June 30, 2022 | 30.38M |
| March 31, 2022 | 3.319M |
| December 31, 2021 | 2.271M |
| September 30, 2021 | 13.20M |
| June 30, 2021 | 14.69M |
| March 31, 2021 | 15.68M |
| December 31, 2020 | 16.68M |
| September 30, 2020 | 7.838M |
| June 30, 2020 | 7.884M |
| March 31, 2020 | 9.749M |
| December 31, 2019 | 9.910M |
| September 30, 2019 | 8.413M |
| June 30, 2019 | 7.317M |
| March 31, 2019 | 4.966M |
| December 31, 2018 | 4.464M |
| September 30, 2018 | 4.944M |
| June 30, 2018 | 5.035M |
| March 31, 2018 | 5.194M |
| Date | Value |
|---|---|
| December 31, 2017 | 5.250M |
| September 30, 2017 | 7.029M |
| June 30, 2017 | 6.245M |
| March 31, 2017 | 6.210M |
| December 31, 2016 | 8.234M |
| September 30, 2016 | 6.003M |
| June 30, 2016 | 6.104M |
| March 31, 2016 | 5.283M |
| December 31, 2015 | 1.879M |
| September 30, 2015 | 0.9299M |
| June 30, 2015 | 2.325M |
| March 31, 2015 | 6.808M |
| December 31, 2014 | 7.008M |
| September 30, 2014 | 14.46M |
| June 30, 2014 | 14.06M |
| March 31, 2014 | 11.02M |
| December 31, 2013 | 12.55M |
| September 30, 2013 | 6.276M |
| June 30, 2013 | 6.992M |
| March 31, 2013 | 6.020M |
| December 31, 2012 | 6.361M |
| September 30, 2012 | 5.234M |
| June 30, 2012 | 4.430M |
| March 31, 2012 | 6.454M |
| December 31, 2011 | 19.33M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
2.271M
Minimum
Dec 2021
33.12M
Maximum
Dec 2022
13.56M
Average
9.081M
Median
Revenue (TTM) Benchmarks
| Abliva AB | -- |
| Karolinska Development AB | 0.1834M |
| Calliditas Therapeutics AB | 123.97M |
| Oncopeptides AB | 2.890M |
| Olink Holding AB | 170.89M |